Investigating women's preference for sildenafil or vardenafil use by their partners with erectile dysfunction: the partners' preference study
Introduction: Several preference studies comparing a short-acting with a longer-acting phosphodiesterase type 5 inhibitor have been conducted in men. Most men in those studies preferred vardenafil rather than sildenafil, and recent post hoc analysis of one study described several factors associated with men's treatment preference. No prospective studies have investigated the woman partners' preferences.
Aim: To investigate the treatment preference of women who were partners of men using oral medications for erectile dysfunction (ED) in a single-center open-label crossover study.
Methods: One hundred heterosexual couples in stable relationships, with male partners having ED based on the erectile function subscale of the International Index of Erectile Function, were randomly assigned to receive sildenafil or vardenafil for a 12-week phase, followed by another 12-week period using the alternate drug. Male and female participants completed sexual event diaries during both study phases, and the female participants were interviewed at baseline, midpoint, and end of study.
Main outcome measures: Primary outcome data were the women's final interviews during which they were asked which drug they preferred and their reasons for that preference.
Results: A total of 79.2% of the women preferred their partners' use of vardenafil, while 15.6% preferred sildenafil. Preference was not affected by age or treatment order randomization. Women preferring vardenafil reported feeling more relaxed, experiencing less pressure, and enjoying a more natural or spontaneous sexual experience as reasons for their choice. Mean number of tablets used, events recorded, events per week, and days between events were not significantly different during each study phase.
Conclusion: Women's preferences were similar to men when using these two drugs. While the women's reasons for preferring vardenafil emphasized relaxed, satisfying, longer-lasting sexual experiences, those preferring sildenafil focused on satisfaction and drug effectiveness for their partner.
Similar articles
Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, Vail GM, Beardsworth A. Eardley I, et al. BJU Int. 2007 Jul;100(1):122-9. doi: 10.1111/j.1464-410X.2007.06916.x. BJU Int. 2007. PMID: 17552960 Clinical Trial.
Lee J, Pommerville P, Brock G, Gagnon R, Mehta P, Krisdaphongs M, Chan M, Chan J, Dickson R. Lee J, et al. BJU Int. 2006 Sep;98(3):623-9. doi: 10.1111/j.1464-410X.2006.06384.x. BJU Int. 2006. PMID: 16925764
Brock G, Chan J, Carrier S, Chan M, Salgado L, Klein AH, Lang C, Horner R, Gutkin S, Dickson R. Brock G, et al. BJU Int. 2007 Feb;99(2):376-82. doi: 10.1111/j.1464-410X.2006.06586.x. Epub 2006 Nov 28. BJU Int. 2007. PMID: 17155989
Doggrell S. Doggrell S. Int J Impot Res. 2007 May-Jun;19(3):281-95. doi: 10.1038/sj.ijir.3901525. Epub 2006 Dec 21. Int J Impot Res. 2007. PMID: 17183346 Review.
Doggrell SA. Doggrell SA. Expert Opin Pharmacother. 2005 Jan;6(1):75-84. doi: 10.1517/14656566.6.1.75. Expert Opin Pharmacother. 2005. PMID: 15709885 Review.
Cited by
Kim M, Noh Y, Yamada A, Hong SH. Kim M, et al. JMIR Med Inform. 2022 Feb 28;10(2):e32689. doi: 10.2196/32689. JMIR Med Inform. 2022. PMID: 35225813 Free PMC article.
Domes T, Najafabadi BT, Roberts M, Campbell J, Flannigan R, Bach P, Patel P, Langille G, Krakowsky Y, Violette PD. Domes T, et al. Can Urol Assoc J. 2021 Dec;15(12):426-428. doi: 10.5489/cuaj.7679. Can Urol Assoc J. 2021. PMID: 34847349 Free PMC article. No abstract available.
Domes T, Najafabadi BT, Roberts M, Campbell J, Flannigan R, Bach P, Patel P, Langille G, Krakowsky Y, Violette PD. Domes T, et al. Can Urol Assoc J. 2021 Oct;15(10):310-322. doi: 10.5489/cuaj.7572. Can Urol Assoc J. 2021. PMID: 34665713 Free PMC article.
Zhou Z, Chen H, Wu J, Wang J, Zhang X, Ma J, Cui Y. Zhou Z, et al. Sex Med. 2019 Sep;7(3):282-291. doi: 10.1016/j.esxm.2019.06.006. Epub 2019 Jul 12. Sex Med. 2019. PMID: 31307951 Free PMC article. Review.
Lee M, Sharifi R. Lee M, et al. Drugs Aging. 2018 Mar;35(3):175-187. doi: 10.1007/s40266-018-0528-4. Drugs Aging. 2018. PMID: 29464656 Review.
Domes T, Najafabadi BT, Roberts M, Campbell J, Flannigan R, Bach P, Patel P, Langille G, Krakowsky Y, Violette PD. Domes T, et al. Can Urol Assoc J. 2021 Dec;15(12):426-428. doi: 10.5489/cuaj.7679. Can Urol Assoc J. 2021. PMID: 34847349 Free PMC article. No abstract available.
Investigating women's preference for sildenafil or vardenafil use by their partners with erectile dysfunction: the partners' preference study
Introduction: Several preference studies comparing a short-acting with a longer-acting phosphodiesterase type 5 inhibitor have been conducted in men. Most men in those studies preferred vardenafil rather than sildenafil, and recent post hoc analysis of one study described several factors associated with men's treatment preference. No prospective studies have investigated the woman partners' preferences.
Aim: To investigate the treatment preference of women who were partners of men using oral medications for erectile dysfunction (ED) in a single-center open-label crossover study.
Methods: One hundred heterosexual couples in stable relationships, with male partners having ED based on the erectile function subscale of the International Index of Erectile Function, were randomly assigned to receive sildenafil or vardenafil for a 12-week phase, followed by another 12-week period using the alternate drug. Male and female participants completed sexual event diaries during both study phases, and the female participants were interviewed at baseline, midpoint, and end of study.
Main outcome measures: Primary outcome data were the women's final interviews during which they were asked which drug they preferred and their reasons for that preference.
Results: A total of 79.2% of the women preferred their partners' use of vardenafil, while 15.6% preferred sildenafil. Preference was not affected by age or treatment order randomization. Women preferring vardenafil reported feeling more relaxed, experiencing less pressure, and enjoying a more natural or spontaneous sexual experience as reasons for their choice. Mean number of tablets used, events recorded, events per week, and days between events were not significantly different during each study phase.
Conclusion: Women's preferences were similar to men when using these two drugs. While the women's reasons for preferring vardenafil emphasized relaxed, satisfying, longer-lasting sexual experiences, those preferring sildenafil focused on satisfaction and drug effectiveness for their partner.
Introduction: Several preference studies comparing a short-acting with a longer-acting phosphodiesterase type 5 inhibitor have been conducted in men. Most men in those studies preferred vardenafil rather than sildenafil, and recent post hoc analysis of one study described several factors associated with men's treatment preference. No prospective studies have investigated the woman partners' preferences.
Similar articles
Can Urol Assoc J.
08.04.2023 12:10:03
2023-04-08 12:10:03